Stockreport

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics Inc. - Class A  (VTVT) 
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vtvtherapeutics.com
PDF HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cad [Read more]